NOV 07, 2017 10:00 AM PST

WEBINAR: Chimeric Antigen Receptors: From proof of concept to widely applicable clinical research solutions

Sponsored by: Miltenyi Biotec
Speaker

Event Date & Time

DATE: November 7, 2017 
TIME: 10:00AM PST

Abstract

Chimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in phase I trials.  In most instances, lentivirus-based or a retrovirus-based gene vectors were used to introduce the therapeutic gene expression cassette into the genome of T lymphocytes.  The gene expression cassette is composed of an internal promoter and the CAR, created by splicing together of extracellular antigen-binding motifs, linker and transmembrane domains, and intracellular lymphocyte signaling domains.  This synthetic engineered receptor can be modified in a number of ways in order to further improve CAR T efficacy and safety.  We have found that the combination of two extracellular binding domains is possible, thus expanding the antigens targeted by a single CAR construct, and potentially providing a more effective barrier to the generation of antigen-escape variants. Making CAR-based immunotherapy broadly available to those in need, requires the ability to isolate, activate, transduce, and expand T cell or NK cell populations in a safe clinically-relevant platform.  The CliniMACS® Prodigy is a closed cell culture system that combines recent advances in lymphocyte isolation (using antibody-conjugated matrices), activation (using an anti-CD3/CD28 nanomatrix), and automated culture using optimized media and cytokines, into a single platform suitable for the introduction of therapeutic gene vectors, lymphocyte transduction, culture and expansion, and final formulation.  Using clinical-grade lentivirus-based gene vectors we have demonstrated the ability to produce CAR-expressing T cells.  The CliniMACS® Prodigy platform provides a standardized solution for broad application of CAR-based therapies in clinical studies.

 

Learning Objectives:

  • Review critical aspects for creating CAR T cells
  • Review process of CAR-modified cell manufacturing

 


You May Also Like
NOV 07, 2017 10:00 AM PST

WEBINAR: Chimeric Antigen Receptors: From proof of concept to widely applicable clinical research solutions

Sponsored by: Miltenyi Biotec


Loading Comments...